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E-mail address: khaliqnaveed2001@yahoo.com (A.Background and objectives: Maternally Inherited Diabetes Mellitus and Deafness (MIDD) occurs due to the
mutations in mitochondrial DNA (mtDNA). The most common heteroplasmic point mutation reported, is
in the tRNALeu(UUR) gene, i.e., A3243G, accompanied with deafness. The objectives of the present study
were to determine whether the cause of MIDD in selected Pakistani population, is also the mutation of
A3243G in mitochondrial tRNALeu(UUR) gene or not, and is there any genotype–phenotype correlation
for the MIDD in this population.
Subjects and methods: The present study was conducted in the Department of Biochemistry and Molec-
ular Biology, ArmyMedical College, Rawalpindi, Pakistan, during the period November 2005 to November
2007. The patients and control subjects were randomly selected from the two cities; Rawalpindi and
Multan (both rural and urban areas) and were divided into three groups. (1) Fifty patients with T2DM
and maternal history with feature(s) of MIDD. (2) Fifty non-diabetic ﬁrst-degree relatives of patients with
T2DM. (3) Fifty non-diabetic controls with no maternal history of T2DM. The patients and control
subjects were scanned for the detection of potential mutations in mitochondrial DNA tRNALeu(UUR) gene
(np 3035–3456, 422 bp fragment).
Results: On the basis of a polymerase chain reaction, electrophoresis and mtDNA sequencing along with
insulin dependence, degree of deafness in patients and subjects, it is proved that there is no A-to-G
mutation at np 3243 of mitochondrial leucine tRNA gene in any of the groups studied.
Conclusion: It is concluded that in the Pakistani population, selected for the present study, the MIDD is
not due to A3243G mutation in mitochondrial tRNALeu(UUR) gene.
 2009 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
Diabetes Mellitus (DM) is a group of metabolic disorders
characterized by hyperglycemia resulting from autoimmune
destruction of b cells (beta cells) of pancreas and genomic deoxyri-
bonucleic acid (DNA) mutations in the gene linked to insulin, insu-
lin receptor, enzyme adenosine deaminase, and glucokinase gene
in type 2 diabetes mellitus [1]. Genetic defects seem to be involved
both in glucose induced insulin secretion and peripheral insulin
sensitivity. Patients who would develop T2DM at later stages of
their life, due to some genetic cause, have a decreased insulin re-
sponse and impaired glucose tolerance even in preclinical period
[2]. Defects in mitochondrial function or mitochondrial DNA
(mtDNA) mutation may lead to impaired insulin secretion. In pan-
creatic b cells, mitochondria are responsible for glucose induced
insulin secretion. Changes in the intracellular ATP/ADP ratio, due
to oxidative phosphorylation in the mitochondria, trigger the exo-
cytosis of insulin containing secretory granules [3].ellitus. Published by Elsevier Ltd. O
x: +92 51 561 32787.
K. Naveed).Mitochondrial DNA has 10 times the rate of spontaneous muta-
tion when compared with nuclear genome. Mitochondrial DNA has
neither protective histones nor an effective DNA repair system, as
present in the nucleus, which makes mitochondria less efﬁcient in
repairing DNA damage [4]. Luft et al. [5] introduced the concept of
mtDNA mutations leading to oxidative phosphorylation disorders.
Mitochondrial diseases can be caused by point mutations, dele-
tions and duplications, which abolish the function of genes in the
densely packed mitochondrial genome. Patients with mitochon-
drial disease often have a mixture of mutant and wild-type mtDNA
(Heteroplasmy) [6]. The pancreatic islet cells, which are metaboli-
cally active, are easily affected by any disruption in oxidative phos-
phorylation, leading to impaired insulin secretion and the
development of diabetes mellitus. Diabetes mellitus, associated
with mitochondrial DNAmutation, is transmitted maternally. With
the discovery of maternally inherited diabetes and deafness
(MIDD), a new subtype of diabetes, it was postulated that diabetes
in these individuals may be developed by an inappropriate oxida-
tive disposal of glucose in peripheral tissues, leading to hypergly-
cemia via enhanced gluconeogenesis [7]. The most common
heteroplasmic point mutation associated with diabetes was foundpen access under CC BY-NC-ND license.
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affects the transcription and translation of mtDNA and has been
found to be one of the causes of type 2 diabetes mellitus with sen-
sorineural hearing loss. Hence, it is called ‘‘maternally inherited
diabetes mellitus and deafness (MIDD)”. Later, other homoplasmic
mutations i.e., G1888A, T4216G, A4917G and T14709C were also
detected and found to play important role in pathogenesis of type
2 diabetes mellitus [8]. In the case of the A3243G mutation, T2DM
results due to a reduction in insulin secretion. Impaired hearing is a
characteristic feature in patients with MIDD and even non-diabetic
carriers of the A3243Gmutation. The mechanism by which the im-
paired hearing is associated with the A3243G mutation is still un-
known. However, the main defect leading to diabetes seems to be
more rapid deterioration of pancreatic b cells, and a failure to se-
crete sufﬁcient amounts of insulin [9]. As there is a lack of litera-
ture which assesses the types of mitochondrial DNA mutation
seen more frequently in population affected with type 2 diabetes
mellitus, the aim of this study was to determine mitochondrial
tRNALeu(UUR) gene mutation in MIDD in Pakistani population, as
this might help to determine genotype–phenotype correlation for
the mentioned disease. Moreover, after ﬁnding such mutation in
the Pakistani population, modulating mitochondrial gene expres-
sion might be helpful in the diagnosis and treatment of maternally
inherited diabetes and deafness.
2. Materials and methods
The present, retrospective, analytical case control study was
conducted in the Department of Biochemistry and Molecular Biol-
ogy, ArmyMedical College, Rawalpindi, Pakistan, during November
2005 to November 2007. Patients were randomly selected from the
Military Hospital, Rawalpindi, the Combined Military Hospital,
Multan and rural areas near Chakri Road, Rawalpindi. Subjects were
subdivided into three groups. Fifty patients with type 2 diabetes
mellitus, a maternal history of diabetes plus one or more features
of mitochondrial disease such as sensorineural hearing loss, onset
of diabetes before age of 40 years, low BMI and progressive insulin
dependence, were grouped together (group 1). Another group com-
prised ﬁfty non-diabetic ﬁrst-degree relatives of the patients with
type 2 diabetes mellitus (group 2), and the last group which com-
prised 50 non-diabetic subjects with no maternal history of diabe-
tes (group 3) were selected as control. The individuals of these
groups were examined for the detection of potential mutations
within the region of mitochondrial DNA tRNALeu(UUR) gene (np
3035–3456, 422 bp fragment) which contains the whole sequence
of tRNALeu(UUR) gene. High molecular weight total genomic DNA
was extracted from peripheral blood leukocytes by kit method
(GENTRA, USA). This was followed by whole genomic ampliﬁcation
of humanmitochondrial DNA by using standard kit method (QiagenFig. 1.1. Electropherogram of Ethidium bromide stained 4% agarose gel for ampliﬁed 422
and deafness; lanes 3&4: patients with T2DM and no complaint of deafness; lanes 5&6
diabetic controls.Repli-G mitochondrial DNA kit). The fragments of mitochondrial
DNA encompassing np 3243 were ampliﬁed by PCR with AmpliTaq
DNA polymerase. Two sets of primers were used. Forward Primer
was 50-CGTTTGTTCAACGATTAAAG-30 covering position 3035–3054
and Reverse Primer was 50-AGCGAAGGGTTGTACTAGML-30 covering
position 3437–3456 [10]. The PCR products (422-bp Fragment of
mtDNA) were electrophoresed on 4% agarose gel stained with
Ethidium Bromide.
2.1. PCR-restriction fragment length polymorphism (PCR-RFLP)
analysis
The 422-bp Fragment of mitochondrial DNA ampliﬁed by PCR
was digested by the restriction enzyme Apa1 (Fermentas Life Sci-
ences) to identify any A-to-G mutation at np 3243 and electropho-
resed on 4% agarose gel stained with Ethidium Bromide. DNA
puriﬁcation was conducted through standard kit method followed
by DNA sequencing PCR. Finally, the PCR products were directly se-
quenced (Beckman Coulter, USA).
Plasma glucose was estimated by the enzymatic colorimetric
method using glucose oxidase enzyme to oxidize glucose [11]. Gly-
cosylated hemoglobin (HbA1c) was determined by micro column
method (ion exchange chromatography) [12].
Obesity was deﬁned as a body mass index (BMI) of 30 kg/m2 or
greater, body weight, excess was deﬁned as BMI of 25 kg/m2 or
greater and low body weight was deﬁned as a BMI less than
18.5 kg/m2 [13].
Audiography was performed to detect the type and extent of
hearing loss [14].
2.2. Statistical analysis
All statistical calculations were conducted through computer
software programme ‘‘Statistical Package for Social Sciences
(SPSS)” for windows, version 15. Data was subsequently examined
by Independent Sample T-test. The percentage was calculated
based on the number of subjects showing positive results, over
the total no of subjects analyzed in each categorized group.
3. Results
3.1. Detection of A3243G mutation
The ampliﬁed PCR product was 422 bp in length. After digestion
with restriction endonuclease, ApaI, it was to be separated into 210
bp or 212 bp if it had a substitution of A to G at np 3243 to consti-
tute the recognition site for ApaI. The results obtained from the less
sensitive method, i.e., ApaI digestion technique (Fig. 1.1), were con-
ﬁrmed by direct sequencing (Figs. 1.2–1.4).bp segment of mitochondrial DNA in control group. Lanes 1&2: patients with T2DM
: ﬁrst-degree relatives of patients with T2DM and deafness group; lanes 7&8: non-
Fig. 1.2. Sequence alignment showing no A to G substitution at 3243 position in mtDNA of patient with T2DM & deafness.
Fig. 1.3. Sequence alignment showing no A to G substitution at 3243 position in mtDNA of the ﬁrst-degree relative of patient with T2DM & deafness.
Fig. 1.4. Sequence alignment showing no A to G substitution at 3243 position in control group.
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patients of type 2 diabetes mellitus were signiﬁcantly higher
(p < 0.001) as compared with the control group. However no signif-
icant differences in plasma glucose and glycosylated hemoglobin
were observed between the ﬁrst-degree relatives of diabetic
patients with control group (Table 1).
In patients with T2DM, BMI was found to be within the normal
range. However, statistically, BMI was signiﬁcantly less (p < 0.05)
in group 1 as compared with control subjects. However, no signif-
icant difference was observed between the ﬁrst-degree relatives of
diabetic patients with their control group.
In patients with T2DM, deafness was observed in 27 patients
(54%). While 50% of the patients were dependent on insulin ther-
apy for the control of the plasma glucose level, the remaining
50% patients were able to control blood glucose level with the help
of oral hypoglycemic drugs (Table 2).Table 2
Body Mass Index (BMI), deafness, Glycosuria and dependence on insulin therapy of patie
group.
Group BMI Mean ± S.E.
Diabetics (50) 22.94 ± 0.39a
First-degree relatives of diabetics (50) 24.20 ± 0.52
Non-diabetic controls (50) 24.52 ± 0.53
a p < 0.05 as compared with normal control subjects (signiﬁcant).
Table 1
Age of onset of T2DM and deafness, plasma glucose and Glycosylated hemoglobin levels
control group.
Group Age of onset of T2DM (years)
Mean ± SD
Age of onset of
Mean ± SD
Diabetics (50) 35.86 ± 5.23 47.56 ± 6.4
First-degree relatives of diabetics
(50)
– –
Non-diabetic controls (50) – –
a p < 0.001 as compared with normal control subjects (highly signiﬁcant).4. Discussion
4.1. A3243G mutation near the region of tRNALeu(UUR) gene in Pakistani
population
The Pakistani population provides a valuable resource for map-
ping mtDNAmutations, as this population is still not explored with
respect to any mitochondria associated disease as compared to
other populations in advanced countries. All 50 patients described
herein have at least three to four dominant clinical features char-
acteristic of MIDD. The results of the search for A3243G mutation
in mitochondrial tRNALeu(UUR) gene in subjects with type 2 diabetes
mellitus in Pakistani population identiﬁed none of the individual as
a carrier of this mutation indicating that the variation within
mtDNA 3035–3456 is not the major cause of type 2 diabetes
mellitus in the selected Pakistani population in this study. Wents with type 2 diabetes mellitus and ﬁrst-degree relatives of diabetics with control
Deafness % Glycosuria % Insulin therapy %
54 76 50
NIL NIL NIL
NIL NIL NIL
of patients with type 2 diabetes mellitus and ﬁrst-degree relatives of diabetics with
deafness (years) Plasma glucose (mmol/L)
Mean ± S.E.
Glycosylated
hemoglobin %
13.36 ± 0.94a 9.39 ± 0.43a
5.01 ± 0.09 5.34 ± 0.09
5.13 ± 0.08 5.55 ± 0.10
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who reported having a maternal history of diabetes, deafness and
insulin dependence.
It should not be excluded that other gene variation may also
play a potential role in the etiology of this disease. Pathogenic
mutations can occur at almost any site throughout the mitochon-
drial genome; hence comprehensive screening requires an analysis
of the entire mtDNA molecule [15]. Moreover, the level of mutated
mtDNA in relation to the wild-type mtDNA (% Heteroplasmy) var-
ies between tissues, being high in post-mitotic tissues such as
endocrine tissues like pancreas, brain and skeletal muscles, and
low in rapidly dividing tissues, such as blood leukocytes [16].
The reliable detection of mitochondrial DNA mutations in T2DM
requires thousands of well-characterized samples. Large popula-
tion based samples are needed to provide an epidemiological con-
text and to characterize susceptible genes. Moreover, direct
sequencing of isolated mitochondrial proteins may provide
evidence as to whether alterations in the primary structure are,
indeed, involved in the pathogenesis of MIDD. We studied 50
patients and there was clear maternal transmission of diabetes in
each pedigree. Our comprehensive search for mtDNA defects,
therefore, allows us to conclude that mechanisms other than inher-
ited defects of mtDNA must be contributing to the maternal trans-
mission of diabetes in these families [17].
Hyperglycemia is a speciﬁc sign of diabetes mellitus and HbA1c
concentration is a strong tool to diagnose the disease [18–20].
4.2. Insulin dependence and BMI
Mostly in T2DM, obesity is one of the causes of insulin resis-
tance [21]. However, the patients in this study had low BMI as
compared with controls, so there must be some other cause of
insulin dependence like pancreatic b cells defect that limits their
ability to secrete or produce insulin [22]. There is evidence that
uncontrolled hyperglycemia in MIDD is due to the impaired ability
of b cells to secrete insulin and respond to the elevated plasma glu-
cose level, not peripheral insulin resistance as in case of maturity
onset type 2 diabetes mellitus of the youth (MODY). This impair-
ment may reﬂect an underlying genetic variation in the genes that
control b cell glucose sensing. There is also evidence that patients
with T2DM may have fewer b cells than non-diabetics. This de-
crease in b cell mass could result from an initial failure to produce
an adequate number of b cells during the development or increase
in b cell impairment. This decline in insulin production capacity
leads to an eventual failure to respond to oral hypoglycemic ther-
apy and requires insulin therapy [23], as in case of present study.
4.3. Deafness
An auditory defect is a progressive bilateral sensorineural hear-
ing loss that ﬁrst affects high frequency sound waves. The most
characteristic audiographic feature is that of sloping, with ﬂat pro-
ﬁles in advanced cases [24]. Mitochondrial pathology plays an
important role in both inherited and acquired hearing loss. Inher-
ited mitochondrial mutations have been implicated in syndromic
and non-syndromic hearing loss [25].
To our knowledge, no other mechanism has been described that
leads to maternal transmission of both diabetes and deafness.
However, sensorineural deafness, like diabetes, is a common condi-
tion and can arise from a large number of autosomal – inherited
gene defects. It is quite possible, therefore, that these 27 patients
with MIDD phenotype were from pedigrees that carried separate
defects, one causing maternally inherited diabetes and the other
leading to deafness [26].
One of the limitations of this study is that the percentage of
mtDNA with mutation varies from tissue to tissue. Unfortunately,the heteroplasmy of the mutation is considered to be much lower
in peripheral leukocytes, and highest in the affected tissues. More-
over, heteroplasmy levels in leukocytes also decline upon aging by
0.7% per year [27]. In the present study, leukocytes were isolated
for DNA extraction. It has probably hampered the detection of this
mutation. In this regard, the pancreas would be the best source of
tissue for the examination of the A3243Gmutation in patients with
diabetes. However, pancreatic biopsy is virtually impossible as a
part of routine screening for logistic reasons. Moreover, due to
the limited funds, sequencing of entire mtDNA was not possible,
so we could not look for other possible mutations.MORE ABOUT THIS STUDY
Another significant finding in this study was raised plasma
triglyceride and total cholesterol (TC) level in patients with
T2DM as compared with first-degree relatives and controls.
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC
Several studies in Japan showed that patients with diabetes
and tRNALeu (UUR) gene mutation had impaired insulin secre-
tion and this mutation played important role in the develop-
ment of diabetes. Patients had shown decreased urinary C-
Peptide excretion. One study carried out in France revealed
a new homoplasmic mutation at position 8381 in the ATPase
8 gene of a MIDD patient. This study also showed the high
prevalence of three other homoplasmic mutations i.e.,
G1888A, T4216G and A4917G in a small group of diabetic pa-
tients as compared to controls. In 2002 in France, a point
mutation inmitochondrial DNA, i.e., T14709Cwas found to ef-
fect mitochondrial function in diabetic patients by a yet
unidentified mechanism. In 2000, a study in China showed
that variation within mitochondrial DNA 3153–3551 was not
the major cause of type 2 diabetes mellitus in the Chinese
population, but another point mutation T to C/T was detected
in mitochondrial nucleotide 3285 located in the highly conser-
vative region of tRNALueUUR.
WHAT THIS STUDY ADDS
In Pakistan, no data is available to assess the types of mito-
chondrial DNA mutations seen more frequently in our pop-
ulation affected with Maternally Inherited Diabetes
Mellitus. It is still to be worked out which type of mitochon-
drial DNA mutation is responsible for impaired glucose tol-
erance in the Pakistani population. This study has sought
the relationship between Maternally Inherited Diabetes Mel-
litus and tRNALeu(UUR) gene mutations in mitochondrial DNA
in Pakistani population.
5. Conclusion
Although previous clinical observations have suggested some
involvement of mitochondrial dysfunctions in the etiology of
maternal inheritance of type 2 diabetes mellitus (MIDD), the
A3243G mutation in mitochondrial tRNALeu(UUR) gene is not likely
to be a frequent cause in Pakistani population. Therefore, the ob-
served clinical features might be the result of a combination of sev-
eral other mechanisms involved in pathogenesis of Type 2 DM
speciﬁed as MIDD. The further screening of a large number of pa-
tients and subjects in three study groups is necessary to fully
determine the prevalence or absence of this mutation in the Paki-
stani population. However, in the present study, there is no case to
search for inherited mtDNA defects in pedigrees with maternally
inherited diabetes alone. It is, therefore, recommend that patients
with maternally inherited diabetes, along with one or more addi-
tional features of mitochondrial disease, should be referred to a
specialist center, as they are likely to need more extensive investi-
gation for mtDNA defects.
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